Precigen, Inc. (PGEN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Randal J. Kirk J.D. | Executive Chairman | 100k | -- | 1953 |
| Dr. Helen Sabzevari MPH, Ph.D. | President, CEO & Director | 1.29M | -- | 1963 |
| Mr. Harry Thomasian Jr. | Chief Financial Officer | 524.04k | -- | 1963 |
| Mr. Rutul R. Shah | Chief Operating Officer | 393.54k | -- | 1981 |
| Mr. Donald P. Lehr | Chief Legal Officer & Corporate Secretary | 652.4k | -- | 1975 |
| Mr. Jeffrey Thomas Perez | Senior Vice President of Intellectual Property Affairs | 570.24k | -- | 1972 |
| Mr. Steven Harasym | VP & Head of Investor Relations | -- | -- | -- |
| Mr. Rob Russell | VP & Head of Human Resources | -- | -- | -- |
| Dr. Douglas E. Brough Ph.D. | Senior VP & Head of Research | -- | -- | 1955 |
| Dr. Bryan T. Butman Ph.D. | Senior VP & Head of CMC | -- | -- | 1953 |
Precigen, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 202
Description
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Corporate Governance
Recent Events
- Mar 19, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 12, 2024CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing
- Jan 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 29, 2023S-3: Offering RegistrationsSee Full Filing